Inhibitory effects of tumor invasion-inhibiting factor 2 and its conjugate on disseminating tumor cells

Tumor invasion-inhibiting factor 2 (IIF-2) is a polypeptide of 21 amino acids which binds to the surface of tumor cells and inhibits experimental invasion in vitro. An albumin conjugate of IIF-2 was used to examine its potential as an antimetastatic compound. The conjugate inhibits in vivo lung meta...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer research (Chicago, Ill.) Ill.), 1994-03, Vol.54 (5), p.1264-1270
Hauptverfasser: ISOAI, A, GOTO-TSUKAMOTO, H, YAMORI, T, OH-HARA, T, TSURUO, T, SILLETTI, S, RAZ, A, WATANABE, H, AKDEO, H, KUMAGAI, H
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1270
container_issue 5
container_start_page 1264
container_title Cancer research (Chicago, Ill.)
container_volume 54
creator ISOAI, A
GOTO-TSUKAMOTO, H
YAMORI, T
OH-HARA, T
TSURUO, T
SILLETTI, S
RAZ, A
WATANABE, H
AKDEO, H
KUMAGAI, H
description Tumor invasion-inhibiting factor 2 (IIF-2) is a polypeptide of 21 amino acids which binds to the surface of tumor cells and inhibits experimental invasion in vitro. An albumin conjugate of IIF-2 was used to examine its potential as an antimetastatic compound. The conjugate inhibits in vivo lung metastasis of various highly metastatic tumor cells, including murine melanoma, colon adenocarcinoma, squamous cell carcinoma, forestomach carcinoma, and human fibrosarcoma. In addition to the anti-lung metastasis activity of this compound, it also showed the inhibitory effects on liver and spleen metastasis of murine T-lymphoma cells. A single administration of the conjugate with melanoma cells resulted in prolonged survival times, and their lung colonization was also inhibited when the conjugate was administrated i.v. at times ranging from 6 h before to 1 h after tumor cell inoculation. Similarly, i.p. administration 1 h prior to melanoma cell injection suppressed lung colonization. Pharmacokinetic analysis revealed that the conjugate was more stable than IIF-2 peptide alone. Approximately 10% of the conjugate remained circulating 2 h postinjection and persisted 20 h without degradation, compared with rapid clearing of the unconjugated IIF-2 peptide within 5 min. Furthermore, spontaneous lung metastasis of murine melanoma and colon adenocarcinoma cell was inhibited by successive i.p. administration of the conjugate before the removal of the primary site, with no effect on primary tumor growth. The conjugate significantly reduced tumor cell arrest in the lung and both the IIF-2 peptide and its conjugate demonstrated potent inhibition of basal as well as cytokine-induced-stimulated tumor cell motility. These results suggest that one mode of IIF-2 action may be inhibition of the extravasation of metastasizing cells which have arrested in a target organ, and that the IIF-2-albumin conjugate may be a potent antimetastatic substance with utility in the prevention of artificial seeding of tumor cells during surgical removal of the primary lesions as well as inhibiting metastasis from established metastases.
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_76388645</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>16814329</sourcerecordid><originalsourceid>FETCH-LOGICAL-h231t-2589a5d411621efb99d2377f290c03faee27d2e1ab8414026879813a10e737fd3</originalsourceid><addsrcrecordid>eNqF0E1LxDAQBuAgyrqu_gQhB_FWyOSjSY-y-LEgeNFzmbbJbpY2WZtW2H9vdYtXT8PwPrwMc0aWoITJtJTqnCwZYyZTUvNLcpXSfloVMLUgCwNgDKgl2W7Czld-iP2RWudsPSQaHR3GLvbUhy9MPobMn5APW-qwnjDlFEND_aTrGPbjFgdLY6CNT8l2PuCvPbXUtm3TNblw2CZ7M88V-Xh6fF-_ZK9vz5v1w2u24wKGjCtToGokQM7BuqooGi60drxgNRMOreW64RawMhIk47nRhQGBwKwW2jViRe5PvYc-fo42DWXn088FGGwcU6lzYUwu1b8QcgNS8GKCtzMcq8425aH3HfbHcn7hlN_NOaYaW9djqH36Y6LImTZGfAPjinsd</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>16814329</pqid></control><display><type>article</type><title>Inhibitory effects of tumor invasion-inhibiting factor 2 and its conjugate on disseminating tumor cells</title><source>MEDLINE</source><source>American Association for Cancer Research</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>ISOAI, A ; GOTO-TSUKAMOTO, H ; YAMORI, T ; OH-HARA, T ; TSURUO, T ; SILLETTI, S ; RAZ, A ; WATANABE, H ; AKDEO, H ; KUMAGAI, H</creator><creatorcontrib>ISOAI, A ; GOTO-TSUKAMOTO, H ; YAMORI, T ; OH-HARA, T ; TSURUO, T ; SILLETTI, S ; RAZ, A ; WATANABE, H ; AKDEO, H ; KUMAGAI, H</creatorcontrib><description>Tumor invasion-inhibiting factor 2 (IIF-2) is a polypeptide of 21 amino acids which binds to the surface of tumor cells and inhibits experimental invasion in vitro. An albumin conjugate of IIF-2 was used to examine its potential as an antimetastatic compound. The conjugate inhibits in vivo lung metastasis of various highly metastatic tumor cells, including murine melanoma, colon adenocarcinoma, squamous cell carcinoma, forestomach carcinoma, and human fibrosarcoma. In addition to the anti-lung metastasis activity of this compound, it also showed the inhibitory effects on liver and spleen metastasis of murine T-lymphoma cells. A single administration of the conjugate with melanoma cells resulted in prolonged survival times, and their lung colonization was also inhibited when the conjugate was administrated i.v. at times ranging from 6 h before to 1 h after tumor cell inoculation. Similarly, i.p. administration 1 h prior to melanoma cell injection suppressed lung colonization. Pharmacokinetic analysis revealed that the conjugate was more stable than IIF-2 peptide alone. Approximately 10% of the conjugate remained circulating 2 h postinjection and persisted 20 h without degradation, compared with rapid clearing of the unconjugated IIF-2 peptide within 5 min. Furthermore, spontaneous lung metastasis of murine melanoma and colon adenocarcinoma cell was inhibited by successive i.p. administration of the conjugate before the removal of the primary site, with no effect on primary tumor growth. The conjugate significantly reduced tumor cell arrest in the lung and both the IIF-2 peptide and its conjugate demonstrated potent inhibition of basal as well as cytokine-induced-stimulated tumor cell motility. These results suggest that one mode of IIF-2 action may be inhibition of the extravasation of metastasizing cells which have arrested in a target organ, and that the IIF-2-albumin conjugate may be a potent antimetastatic substance with utility in the prevention of artificial seeding of tumor cells during surgical removal of the primary lesions as well as inhibiting metastasis from established metastases.</description><identifier>ISSN: 0008-5472</identifier><identifier>EISSN: 1538-7445</identifier><identifier>PMID: 8118815</identifier><identifier>CODEN: CNREA8</identifier><language>eng</language><publisher>Philadelphia, PA: American Association for Cancer Research</publisher><subject>Albumins - chemistry ; Albumins - pharmacology ; Angiogenesis Inducing Agents - antagonists &amp; inhibitors ; Angiogenesis Inhibitors ; Animals ; Antineoplastic agents ; Biological and medical sciences ; Cell Movement - drug effects ; Chemotherapy ; Drug Administration Routes ; Drug Administration Schedule ; Female ; Glucose-6-Phosphate Isomerase - pharmacology ; Humans ; Idoxuridine - pharmacokinetics ; Iodine Radioisotopes ; Lung - metabolism ; Medical sciences ; Mice ; Mice, Inbred Strains ; Neoplasm Metastasis - prevention &amp; control ; Neoplasms, Experimental - drug therapy ; Neoplasms, Experimental - pathology ; Pharmacology. Drug treatments ; Proteins - chemistry ; Proteins - therapeutic use ; Tissue Distribution ; Tumor Cells, Cultured - drug effects</subject><ispartof>Cancer research (Chicago, Ill.), 1994-03, Vol.54 (5), p.1264-1270</ispartof><rights>1994 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=3960788$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8118815$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>ISOAI, A</creatorcontrib><creatorcontrib>GOTO-TSUKAMOTO, H</creatorcontrib><creatorcontrib>YAMORI, T</creatorcontrib><creatorcontrib>OH-HARA, T</creatorcontrib><creatorcontrib>TSURUO, T</creatorcontrib><creatorcontrib>SILLETTI, S</creatorcontrib><creatorcontrib>RAZ, A</creatorcontrib><creatorcontrib>WATANABE, H</creatorcontrib><creatorcontrib>AKDEO, H</creatorcontrib><creatorcontrib>KUMAGAI, H</creatorcontrib><title>Inhibitory effects of tumor invasion-inhibiting factor 2 and its conjugate on disseminating tumor cells</title><title>Cancer research (Chicago, Ill.)</title><addtitle>Cancer Res</addtitle><description>Tumor invasion-inhibiting factor 2 (IIF-2) is a polypeptide of 21 amino acids which binds to the surface of tumor cells and inhibits experimental invasion in vitro. An albumin conjugate of IIF-2 was used to examine its potential as an antimetastatic compound. The conjugate inhibits in vivo lung metastasis of various highly metastatic tumor cells, including murine melanoma, colon adenocarcinoma, squamous cell carcinoma, forestomach carcinoma, and human fibrosarcoma. In addition to the anti-lung metastasis activity of this compound, it also showed the inhibitory effects on liver and spleen metastasis of murine T-lymphoma cells. A single administration of the conjugate with melanoma cells resulted in prolonged survival times, and their lung colonization was also inhibited when the conjugate was administrated i.v. at times ranging from 6 h before to 1 h after tumor cell inoculation. Similarly, i.p. administration 1 h prior to melanoma cell injection suppressed lung colonization. Pharmacokinetic analysis revealed that the conjugate was more stable than IIF-2 peptide alone. Approximately 10% of the conjugate remained circulating 2 h postinjection and persisted 20 h without degradation, compared with rapid clearing of the unconjugated IIF-2 peptide within 5 min. Furthermore, spontaneous lung metastasis of murine melanoma and colon adenocarcinoma cell was inhibited by successive i.p. administration of the conjugate before the removal of the primary site, with no effect on primary tumor growth. The conjugate significantly reduced tumor cell arrest in the lung and both the IIF-2 peptide and its conjugate demonstrated potent inhibition of basal as well as cytokine-induced-stimulated tumor cell motility. These results suggest that one mode of IIF-2 action may be inhibition of the extravasation of metastasizing cells which have arrested in a target organ, and that the IIF-2-albumin conjugate may be a potent antimetastatic substance with utility in the prevention of artificial seeding of tumor cells during surgical removal of the primary lesions as well as inhibiting metastasis from established metastases.</description><subject>Albumins - chemistry</subject><subject>Albumins - pharmacology</subject><subject>Angiogenesis Inducing Agents - antagonists &amp; inhibitors</subject><subject>Angiogenesis Inhibitors</subject><subject>Animals</subject><subject>Antineoplastic agents</subject><subject>Biological and medical sciences</subject><subject>Cell Movement - drug effects</subject><subject>Chemotherapy</subject><subject>Drug Administration Routes</subject><subject>Drug Administration Schedule</subject><subject>Female</subject><subject>Glucose-6-Phosphate Isomerase - pharmacology</subject><subject>Humans</subject><subject>Idoxuridine - pharmacokinetics</subject><subject>Iodine Radioisotopes</subject><subject>Lung - metabolism</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Mice, Inbred Strains</subject><subject>Neoplasm Metastasis - prevention &amp; control</subject><subject>Neoplasms, Experimental - drug therapy</subject><subject>Neoplasms, Experimental - pathology</subject><subject>Pharmacology. Drug treatments</subject><subject>Proteins - chemistry</subject><subject>Proteins - therapeutic use</subject><subject>Tissue Distribution</subject><subject>Tumor Cells, Cultured - drug effects</subject><issn>0008-5472</issn><issn>1538-7445</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1994</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqF0E1LxDAQBuAgyrqu_gQhB_FWyOSjSY-y-LEgeNFzmbbJbpY2WZtW2H9vdYtXT8PwPrwMc0aWoITJtJTqnCwZYyZTUvNLcpXSfloVMLUgCwNgDKgl2W7Czld-iP2RWudsPSQaHR3GLvbUhy9MPobMn5APW-qwnjDlFEND_aTrGPbjFgdLY6CNT8l2PuCvPbXUtm3TNblw2CZ7M88V-Xh6fF-_ZK9vz5v1w2u24wKGjCtToGokQM7BuqooGi60drxgNRMOreW64RawMhIk47nRhQGBwKwW2jViRe5PvYc-fo42DWXn088FGGwcU6lzYUwu1b8QcgNS8GKCtzMcq8425aH3HfbHcn7hlN_NOaYaW9djqH36Y6LImTZGfAPjinsd</recordid><startdate>19940301</startdate><enddate>19940301</enddate><creator>ISOAI, A</creator><creator>GOTO-TSUKAMOTO, H</creator><creator>YAMORI, T</creator><creator>OH-HARA, T</creator><creator>TSURUO, T</creator><creator>SILLETTI, S</creator><creator>RAZ, A</creator><creator>WATANABE, H</creator><creator>AKDEO, H</creator><creator>KUMAGAI, H</creator><general>American Association for Cancer Research</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7TO</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>19940301</creationdate><title>Inhibitory effects of tumor invasion-inhibiting factor 2 and its conjugate on disseminating tumor cells</title><author>ISOAI, A ; GOTO-TSUKAMOTO, H ; YAMORI, T ; OH-HARA, T ; TSURUO, T ; SILLETTI, S ; RAZ, A ; WATANABE, H ; AKDEO, H ; KUMAGAI, H</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-h231t-2589a5d411621efb99d2377f290c03faee27d2e1ab8414026879813a10e737fd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1994</creationdate><topic>Albumins - chemistry</topic><topic>Albumins - pharmacology</topic><topic>Angiogenesis Inducing Agents - antagonists &amp; inhibitors</topic><topic>Angiogenesis Inhibitors</topic><topic>Animals</topic><topic>Antineoplastic agents</topic><topic>Biological and medical sciences</topic><topic>Cell Movement - drug effects</topic><topic>Chemotherapy</topic><topic>Drug Administration Routes</topic><topic>Drug Administration Schedule</topic><topic>Female</topic><topic>Glucose-6-Phosphate Isomerase - pharmacology</topic><topic>Humans</topic><topic>Idoxuridine - pharmacokinetics</topic><topic>Iodine Radioisotopes</topic><topic>Lung - metabolism</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Mice, Inbred Strains</topic><topic>Neoplasm Metastasis - prevention &amp; control</topic><topic>Neoplasms, Experimental - drug therapy</topic><topic>Neoplasms, Experimental - pathology</topic><topic>Pharmacology. Drug treatments</topic><topic>Proteins - chemistry</topic><topic>Proteins - therapeutic use</topic><topic>Tissue Distribution</topic><topic>Tumor Cells, Cultured - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>ISOAI, A</creatorcontrib><creatorcontrib>GOTO-TSUKAMOTO, H</creatorcontrib><creatorcontrib>YAMORI, T</creatorcontrib><creatorcontrib>OH-HARA, T</creatorcontrib><creatorcontrib>TSURUO, T</creatorcontrib><creatorcontrib>SILLETTI, S</creatorcontrib><creatorcontrib>RAZ, A</creatorcontrib><creatorcontrib>WATANABE, H</creatorcontrib><creatorcontrib>AKDEO, H</creatorcontrib><creatorcontrib>KUMAGAI, H</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer research (Chicago, Ill.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>ISOAI, A</au><au>GOTO-TSUKAMOTO, H</au><au>YAMORI, T</au><au>OH-HARA, T</au><au>TSURUO, T</au><au>SILLETTI, S</au><au>RAZ, A</au><au>WATANABE, H</au><au>AKDEO, H</au><au>KUMAGAI, H</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Inhibitory effects of tumor invasion-inhibiting factor 2 and its conjugate on disseminating tumor cells</atitle><jtitle>Cancer research (Chicago, Ill.)</jtitle><addtitle>Cancer Res</addtitle><date>1994-03-01</date><risdate>1994</risdate><volume>54</volume><issue>5</issue><spage>1264</spage><epage>1270</epage><pages>1264-1270</pages><issn>0008-5472</issn><eissn>1538-7445</eissn><coden>CNREA8</coden><abstract>Tumor invasion-inhibiting factor 2 (IIF-2) is a polypeptide of 21 amino acids which binds to the surface of tumor cells and inhibits experimental invasion in vitro. An albumin conjugate of IIF-2 was used to examine its potential as an antimetastatic compound. The conjugate inhibits in vivo lung metastasis of various highly metastatic tumor cells, including murine melanoma, colon adenocarcinoma, squamous cell carcinoma, forestomach carcinoma, and human fibrosarcoma. In addition to the anti-lung metastasis activity of this compound, it also showed the inhibitory effects on liver and spleen metastasis of murine T-lymphoma cells. A single administration of the conjugate with melanoma cells resulted in prolonged survival times, and their lung colonization was also inhibited when the conjugate was administrated i.v. at times ranging from 6 h before to 1 h after tumor cell inoculation. Similarly, i.p. administration 1 h prior to melanoma cell injection suppressed lung colonization. Pharmacokinetic analysis revealed that the conjugate was more stable than IIF-2 peptide alone. Approximately 10% of the conjugate remained circulating 2 h postinjection and persisted 20 h without degradation, compared with rapid clearing of the unconjugated IIF-2 peptide within 5 min. Furthermore, spontaneous lung metastasis of murine melanoma and colon adenocarcinoma cell was inhibited by successive i.p. administration of the conjugate before the removal of the primary site, with no effect on primary tumor growth. The conjugate significantly reduced tumor cell arrest in the lung and both the IIF-2 peptide and its conjugate demonstrated potent inhibition of basal as well as cytokine-induced-stimulated tumor cell motility. These results suggest that one mode of IIF-2 action may be inhibition of the extravasation of metastasizing cells which have arrested in a target organ, and that the IIF-2-albumin conjugate may be a potent antimetastatic substance with utility in the prevention of artificial seeding of tumor cells during surgical removal of the primary lesions as well as inhibiting metastasis from established metastases.</abstract><cop>Philadelphia, PA</cop><pub>American Association for Cancer Research</pub><pmid>8118815</pmid><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0008-5472
ispartof Cancer research (Chicago, Ill.), 1994-03, Vol.54 (5), p.1264-1270
issn 0008-5472
1538-7445
language eng
recordid cdi_proquest_miscellaneous_76388645
source MEDLINE; American Association for Cancer Research; EZB-FREE-00999 freely available EZB journals
subjects Albumins - chemistry
Albumins - pharmacology
Angiogenesis Inducing Agents - antagonists & inhibitors
Angiogenesis Inhibitors
Animals
Antineoplastic agents
Biological and medical sciences
Cell Movement - drug effects
Chemotherapy
Drug Administration Routes
Drug Administration Schedule
Female
Glucose-6-Phosphate Isomerase - pharmacology
Humans
Idoxuridine - pharmacokinetics
Iodine Radioisotopes
Lung - metabolism
Medical sciences
Mice
Mice, Inbred Strains
Neoplasm Metastasis - prevention & control
Neoplasms, Experimental - drug therapy
Neoplasms, Experimental - pathology
Pharmacology. Drug treatments
Proteins - chemistry
Proteins - therapeutic use
Tissue Distribution
Tumor Cells, Cultured - drug effects
title Inhibitory effects of tumor invasion-inhibiting factor 2 and its conjugate on disseminating tumor cells
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T22%3A04%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Inhibitory%20effects%20of%20tumor%20invasion-inhibiting%20factor%202%20and%20its%20conjugate%20on%20disseminating%20tumor%20cells&rft.jtitle=Cancer%20research%20(Chicago,%20Ill.)&rft.au=ISOAI,%20A&rft.date=1994-03-01&rft.volume=54&rft.issue=5&rft.spage=1264&rft.epage=1270&rft.pages=1264-1270&rft.issn=0008-5472&rft.eissn=1538-7445&rft.coden=CNREA8&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E16814329%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=16814329&rft_id=info:pmid/8118815&rfr_iscdi=true